A Continuously Updating Multiomic Oncology Platform
Panel Tests Freeze Patients in Time. Cancer Doesn’t.
Legacy diagnostic tests analyze a restricted set of genes and produce a static one-time report. These results become outdated the moment new therapies, biomarkers, or trials appear.
Technical limitations of the status quo:
- Restricted gene coverage
- No tumour–normal resolution
- No RNA or expression-level insight
- No structural variant detection
- No continuous surveillance as global evidence evolves
- No alerts when new treatments become relevant
- No support for off-label DIN therapy decisions or SAP pathways
- No integration with evolving global evidence
The result? Nearly 88% of patients receive reports stating “no actionable findings”, not because options don’t exist, but because legacy tests cannot see them.
GenTraceDx changes this.
The First Continuously Updating Multiomic Oncology Platform
GenTraceDx integrates three powerful technologies into a single clinical intelligence system:
1. Tumour–Normal Whole Exome Sequencing (WES)
What it captures:
- Rare variants
- Novel driver mutations
- Copy number changes
- Structural variants
- Actionable genomic signatures outside panel limits
Why it matters:
WES expands the range of clinically meaningful findings beyond fixed panel tests, enabling deeper insight into tumour biology.
2. Whole Transcriptome RNA Sequencing
What it captures:
- Gene expression signatures
- Oncogenic pathway activation
- RNA fusions
- Transcript-level biomarkers
- Expression-driven drug sensitivity patterns
Why it matters:
RNA unlocks the “functional biology” of the tumour, revealing which pathways are active and which targeted therapies may be relevant, even when DNA alone is ambiguous.
3. Agentic AI Discovery and Reanalysis Engine
What it does:
Autonomous Clinical Surveillance of global evidence sources as new information emerges:
- FDA/EMA drug approvals
- NCCN and ESMO guideline updates
- New biomarker publications
- Clinical trial openings
- Therapeutic response literature
- Real-world evidence datasets
- Molecular registry updates
When new evidence matches a patient’s tumour profile, the engine:
- Automatically reanalyzes their WES+RNA
- Generates new insights
- Notifies the treating physician and patient
Why it matters:
This transforms precision oncology from a static snapshot into a living clinical intelligence system that evolves with the science.
Dynamic Interpretation:
| Traditional CDx Panels | GenTraceDx Platform |
|---|---|
| Limited Gene Panel | Matched Tumour–Normal WES |
| DNA-Only (Static Snapshot) | Whole Transcriptome RNA |
| One-Time Test Report | Agentic AI Continuous Discovery |
| On-Label Matches Only | On-Label + Off-Label DIN Options |
| No Evidence Updates (Outdated) | Real-Time Global Evidence Alerts |
| Misses Clinical Trial Opportunities | Multiomic Trial Matching Engine |
| Misses Special Access (SAP) Pathways | Surfaces SAP Therapeutic Pathways |
| No Support for Treatment Design | Informs Personalized Cancer Vaccines |
Traditional CDx
- One-time test
- Limited gene panel
- No updates
- Only reports on label-matched therapies
- Misses off-label opportunities and SAP pathways
GentraceDx
- Full tumour–normal WES
- Whole transcriptome RNA
- AI-driven reanalysis
- Notifications as new therapies emerge
- Identifies off-label DIN opportunities
- Surfaces SAP pathways
- Matches trials that static tests don’t detect
- Links to personalized neoantigen vaccine insights
This is the new standard for precision oncology.
We Can Identify Options That Static Tests Miss Completely
- On-label targeted therapies (traditional CDx signatures)
- Off-label DIN-approved therapies (biomarker-driven)
- Special Access Program (SAP) eligible treatments
- Combination therapies based on pathway activation
- Trial-matching using comprehensive multiomic profiles
- Neoantigen vaccine design data for personalized immunotherapies
GenTraceDx is not just a diagnostic; it is a Therapeutic Discovery Engine.
How Living Diagnostics Change Lives
A patient with advanced gastric cancer had exhausted eight years of treatment.
Every legacy panel test reported “no actionable findings.”
The GenTraceDx Discovery Engine revealed:
- High CLDN18.2 expression, a biomarker legacy panels were unable to detect at the time.
- Identified zolbetuximab as a viable third-line off-label therapy 6 months before it reached standard clinical awareness.
- Identified multiple Special Access Pathways (SAPs) for immediate treatment.
- Provided actionable signals to design a personalized neoantigen SLP vaccine (resulting in Canada’s first-ever OLIP CTA-approved trial).
Existing tests missed all of this. GenTraceDx found it.
Precise. Actionable. Continuously Updated.
Our clinician dashboard includes:
- Therapy summaries (on-label + off-label DIN options)
- Special Access Program (SAP) pathways
- Clinical trial-matching
- Proactive agentic AI-driven update alerts
- Variant-level evidence with citations
- WES/RNA visualizations
- PDF clinical reports
- Patient tracking across updates
Integrated Clinical Workflow
Our platform provides prioritized, evidence-linked insights to accelerate clinical decision-making at the point of care.
A Strategic Partnership of Science and Infrastructure
Validated. Scalable. Clinically Ready.
GenTraceDx brings together the scientific leadership of the GSC with the commercial and digital infrastructure of Genetrack.
Genetrack Biolabs
- Global Logistics & Manufacturing: A distribution network spanning 60+ countries including exclusive white-label manufacturing for CVS Pharmacy and Walgreens.
- Established Digital Infrastructure: Proprietary physician and patient portals currently managing secure clinical data for over 3 million patients worldwide.
- Regulatory Compliance: 26 years of FDA and Health Canada regulated diagnostics with ISO and GMP certified facilities.
Genome Sciences Centre (GSC)
- Clinical-Grade Multiomics: A global pioneer in matched tumour–normal WES and whole-transcriptome RNA analysis at scale.
- The Global Knowledge Standard: Developed GraphKB, the Nature-published architecture that unifies fragmented global clinical evidence.
- Accredited Clinical Pipelines: CAP/CLIA/DAP accredited workflows that have sequenced thousands of advanced cancer patients to date.